Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EBCC calls for European countries to speed access to innovative advances for all breast cancer patients

24.03.2006


Breast cancer specialists and advocates at the 5th European Breast Cancer Conference (EBCC-5) called today for patients to have equal and speedy access to new breast cancer treatments and procedures, as soon as they are validated by comparative clinical trials.



Doctors and patient groups fear that women across Europe are not getting timely access to new drugs and devices that could help prolong their survival and well-being. Recent advances in intra-operative radiation therapy and reconstructive surgery to the breast have been made accessible quickly to women in the United States, but even getting on to the relevant clinical trial has proved almost impossible for their European counterparts.

Last year Italian and English studies demonstrated the feasibility of intra-operative radio- therapy. They found that delivering radiation directly to the open breast during surgery appeared to be potentially as effective as six weeks of external radiotherapy. Patients had their breast cancer surgically removed and their radiotherapy treatment all in one stay in hospital. The new treatment also limited radiation exposure to the rest of the patients’ skin and other organs, preventing further tissue damage. However, there are only a few centres across Europe that can carry out intra-operative radiotherapy and many patients cannot benefit from these advances. Patients are still facing long waiting times and have to travel long and tiring distances to radiotherapy centres.


The psychological impact of having a breast removed due to cancer has been well documented. However, new advances in reconstructive breast surgery can significantly improve a patient’s confidence and well-being; unfortunately these surgical techniques are not available to all European patients. Breast surgeons can now perform a mastectomy that removes the malignant tumour and surrounding breast tissue whilst sparing the nipple. Nipple saving surgery can vastly improve the look and feel of the breast and improve a patient’s self confidence.

Surgeons can now reconstruct a breast immediately after the cancer is removed using artificial implants or even the body’s own tissue (autologous tissue reconstruction) or a combination of tissue reconstruction and implants. Breast reconstruction is a complex procedure that needs to be performed by a skilled plastic surgeon, unfortunately not all patients have access to surgeons who can carry out these new techniques.

Another topical example of complexity in access to treatments is the case of the drug trastuzumab (Herceptin). Currently the drug is licensed by the EMEA (European Medicines Agency) for women with advanced stage breast cancer but not for those with the early stages of the disease. The recent results of four large clinical trials showed a significant reduction in breast cancer recurrence for women with HER2 positive breast cancer, when given the drug post-surgery. Breast cancer doctors claim that the results of the four trials are sufficiently compelling to recommend adjuvant trastuzumab as a standard option after surgery in appropriate patients. The lagtime between the announcement of the results of the clinical trials and the submission of the applications by the industry, the lack of clear definition of ‘appropriate patients’, the diversity of the national healthcare systems (even within the EU) and their heterogeneous policies of reimbursement may prevent hundreds of patients enjoying the benefits of this drug when they need it.

Dr Alberto Costa, President of the EBCC-5 conference comments, “Action needs to be taken so that women in different countries have equal and quick access to new and better treatments and procedures. It is regrettable that so many women are still not receiving the treatment that gives them the best chance of survival and best quality of life.”

EBCC-5 Press Office | alfa
Further information:
http://www.fecs.be/emc.asp?pageId=611&Type=P

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

How gut bacteria can make us ill

18.01.2017 | Life Sciences

On track to heal leukaemia

18.01.2017 | Health and Medicine

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>